Rocephin PI updated to reflect calcium interaction
Ceftriaxone prescribing information updated to warn of calcium interaction
Revisions have been made to the label of ceftriaxone (Rocephin, Roche) to include warning of the potential risk of crystallization when the antibiotic is used concomitantly with calcium or calcium-containing solutions or products. The update advises healthcare professionals to avoid coadministration, including with continuous infusions of calcium-containing parenterals such as TPN, even via different sites. Ceftriaxone and calcium solutions should not be administered within 48 hours of each other in any patient, regardless of age.
Click here to see more articles from Drug Topics Daily News.
To go to the Drug Topics homepage, click here.
Pharmacists Play Unique Role in Advancing Health Equity for Patients With Chronic Disease
December 7th 2023A new study, outlined in a poster at ASHP Midyear 2023, identified 3 key themes associated with the ways in which pharmacists are positioned to advance health equity for patients with chronic diseases.
